Increased titer of anticardiolipin antibodies represents the risk for the development of ischemic brain disease in persons below 50.
The aim of this paper was to investigate the frequency of increased ACLA titer in patients with ischemic brain disease (IBD) and to define their clinical profile. The group consisted of 162 IBD patients of both sexes, aged 39-81 years, with 50 healthy volunteers and 23 patients with other neurological diseases as control. Increased ACLA titer (above 0.9 GPL U/l IgG and 0.5 MPL U/l IgM) was registered in 17.9% IBD patients, and more frequently in patients with transitory ischemic attacks (TIA)-32.6%; slightly increased titer predominated (0.9-20 GPL U/l IgG and 0.5-15 MPL U/l IgM) in 69% IBD patients, while moderately increased (20-80 GPL U/l and 15-50 MPL U/l IgM) was present in 21% IBD patients, while highly increased titer (above 80 GPL U/l IgG and above 50 MPL U/l IgM) was present in 10.3%; IgG class was most frequently increased (9.2%), than IgM-5%, while increase of both classes was present in 3.7%. All patients with increased ACLA titer were below 50 years of age, had history of previous IBD attacks, more often TIA, irregularity of at least one coagulation test and fewer risk factors for IBD. Hence, increased ACLA titer was present in IBD patients of both sexes, below 50 years of age with previous history of IBD attacks and fewer atherosclerosis risk factors.